News Release Details
Rocket Pharmaceuticals Supports Rare Disease Day® and Joins Global Movement to Raise Awareness
Feb 6, 2020
—Educational Event at Carnegie Hall Featuring Patient Discussions and Opportunities for Patients and Families to Engage with Physicians and Researchers in the NY Healthcare Community—
—Empire State Building to Illuminate in Pink, Blue, Purple and Green in Honor of Rare Disease Day–
The theme of Rocket’s Rare Disease Day event, hosted in partnership with the
The event will highlight patient artists who raise awareness of their disease through their artwork. At the event, patients will share their personal experiences living with a rare disease, and attendees will have an opportunity to engage in discussions with patients, caregivers, patient advocates, researchers and physicians. The purpose of the event is to provide all who attend an opportunity to learn more about rare disease and the need for new treatment options. In conjunction with the event, for the second year in a row the
“At Rocket, our focus is first and foremost on the patients we are endeavoring to serve, and Rare Disease Day is the perfect time to not only bring that focus to the forefront of everyone’s mind, but to give patients the opportunity to tell their stories and give researchers and those working in biotech a better understanding of the incredible individuals within the rare disease community,” said
According to the
Rare Disease Day takes place every year on the last day of February (
For more information about Rare Disease Day in the U.S. or “Show Your Stripes,” go to www.rarediseaseday.us. For information about global activities, go to www.rarediseaseday.org. To search for information about rare diseases, visit NORD’s website, www.rarediseases.org.
Rocket Cautionary Statement Regarding Forward-Looking Statements
Various statements in this release concerning Rocket's future expectations, plans and prospects, including without limitation, Rocket's expectations regarding the safety, effectiveness and timing of product candidates that Rocket may develop, to treat Fanconi Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD-I), Pyruvate Kinase Deficiency (PKD), Infantile Malignant Osteopetrosis (IMO) and Danon Disease, and the safety, effectiveness and timing of related pre-clinical studies and clinical trials, may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws and are subject to substantial risks, uncertainties and assumptions. You should not place reliance on these forward-looking statements, which often include words such as "believe," "expect," "anticipate," "intend," "plan," "will give," "estimate," "seek," "will," "may," "suggest" or similar terms, variations of such terms or the negative of those terms. Although Rocket believes that the expectations reflected in the forward-looking statements are reasonable, Rocket cannot guarantee such outcomes. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, Rocket's ability to successfully demonstrate the efficacy and safety of such products and pre-clinical studies and clinical trials, its gene therapy programs, the preclinical and clinical results for its product candidates, which may not support further development and marketing approval, the potential advantages of Rocket's product candidates, actions of regulatory agencies, which may affect the initiation, timing and progress of pre-clinical studies and clinical trials of its product candidates, Rocket's and its licensors’ ability to obtain, maintain and protect its and their respective intellectual property, the timing, cost or other aspects of a potential commercial launch of Rocket's product candidates, Rocket's ability to manage operating expenses, Rocket's ability to obtain additional funding to support its business activities and establish and maintain strategic business alliances and new business initiatives, Rocket's dependence on third parties for development, manufacture, marketing, sales and distribution of product candidates, the outcome of litigation, and unexpected expenditures, as well as those risks more fully discussed in the section entitled "Risk Factors" in Rocket's Quarterly Report on Form 10-Q for the quarter ended
View source version on businesswire.com: https://www.businesswire.com/news/home/20200206005246/en/
Claudine Prowse, Ph.D.
SVP, Strategy & Corporate Development